History

Our senior management team has been engaged in life science real estate dating back to the 1980s and includes the founders of the industry, Alan Gold (Chairman and Chief Executive Officer) and Gary Kreitzer (Executive Vice President, General Counsel and Director). Together with a small team of visionaries, Alan and Gary identified the opportunity to apply an institutional investment focus to the underserved life science sector of the real estate market.

1989Alan Gold forms Goldstone Real Estate Finance and Investments and establishes the business model for institutional ownership of office and laboratory space for the life science industry.
1997Alan Gold and Gary Kreitzer serve as President and Senior Vice President/In-House Counsel, respectively, for Health Science Properties Trust which executes an initial public offering as Alexandria Real Estate Equities.
December 1998Alan Gold and Gary Kreitzer leave Alexandria Real Estate Equities and form Bernardo Property Advisors, Inc. to acquire and manage lab space properties for lease to the life science industry.
August 2004BioMed Realty Trust, Inc., a real estate investment trust (REIT), is formed out of Bernardo Property Advisors, Inc. and executes an initial public offering, trading on the New York Stock Exchange under the ticker symbol “BMR”.

Matthew McDevitt joins BioMed as Vice President, Acquisitions.
August – December 2004Subsequent investments in life science properties in San Diego, San Francisco, Seattle, New York, Pennsylvania and Maryland total, including The Landmark at Eastview in Tarrytown, New York.
May 2005A portfolio of seven life science lab space properties in Cambridge, Massachusetts and one property in Lebanon, New Hampshire are acquired, with existing tenants including Genzyme Corporation and Vertex Pharmaceuticals.
March 2006Kent Griffin joins BioMed as Chief Financial Officer.
May 2006Shady Grove Road in Rockville, Maryland, which serves as Human Genome Sciences’ 635,000 square foot corporate headquarters and laboratory and manufacturing facilities, is acquired in a long-term sale-leaseback transaction, along with their 290,000 square foot large scale manufacturing facility and adjacent undeveloped land which can support up to an estimated 500,000 rentable square feet of lab space and office facilities.
July 2006The Pacific Research Center campus in Newark, California is acquired. The property includes ten buildings comprising approximately 1.4 million square feet of office and lab space, as well as undeveloped land.
November 2006The Center for Life Science | Boston is acquired, an over 700,000 square foot, state-of-the-art life science building under development at the time of purchase. Located in the heart of Boston's Longwood Medical area, CLSB’s lab space and office facilities are currently over 90% leased on a long-term basis, with tenants including Beth Israel Deaconess Medical Center, Children's Hospital Boston, Dana-Farber Cancer Institute, Kowa Company and the Immune Disease Institute.
February 2007Illumina signs new leases at the Towne Centre Drive property in San Diego totaling 195,000 square feet, including an expansion into a new build-to-suit with 84,000 square feet of office and lab space.
April 2007A joint venture is formed with Prudential Real Estate Investors (PREI®) to complete the acquisition of a portfolio of properties in Cambridge, Massachusetts, including approximately 600,000 square feet of life science space completed or under construction and land that can support approximately an estimated 266,000 square feet of life science laboratory and office space.
October 2008Novo Nordisk A/S signs new lease for approximately 36,900 square feet of office and lab space at the Fairview Research Center in Seattle.
November 2008Children’s Hospital Boston, a pre-eminent pediatric research institution and teaching affiliate of the Harvard Medical School, signs an amendment to its lease at the Center for Life Science | Boston for an additional 49,000 square feet, bringing its total occupancy in the facility to over 150,000 square feet.

Alan Gold, BioMed's Chairman and Chief Executive Officer, receives the national Ernst & Young LLP Entrepreneur Of The Year® 2008 Award in the Real Estate, Construction and Hospitality category.
December 2008Kent Griffin is promoted to President and Chief Operating Officer of BioMed.
January 2009Vertex Pharmaceuticals signs early extensions and renewals on two leases totaling in excess of 292,000 square feet of space through December 31, 2015 in Cambridge, Massachusetts, including its corporate headquarters.

Kowa Company, one of Japan’s largest privately owned companies and its fifth largest trading company, signs a new lease at the Center for Life Science | Boston for approximately 24,400 square feet of laboratory and office space. The Center for Life Science | Boston is approximately 91% leased.
March 2009Center for Life Science | Boston (CLSB) receives Gold LEED® certification.
June 2009BioMed closes on a five-year, $350 million financing for the Center for Life Science | Boston and an $18 million financing for its 9865 Towne Centre Drive property.
October – December 2009In October, BioMed and Regeneron Pharmaceuticals host a ribbon-cutting ceremony to celebrate the completion of Regeneron's new 229,000 square foot corporate headquarters and research facility developed by BioMed at The Landmark at Eastview in Tarrytown, New York. In December, BioMed enters into a new lease with Regeneron for an additional 131,000 square feet of newly-constructed laboratory and office space at The Landmark campus.
February 2010Matthew McDevitt is promoted to Executive Vice President, Real Estate.
March – May 2010BioMed acquires two properties comprised of seven fully-leased life science buildings and approximately 300,000 square feet located along the I-270 Corridor in Montgomery County, Maryland. Tenants include MedImmune, Inc., a wholly-owned subsidiary of AstraZenica PLC and the J. Craig Venter Institute, a world leader in genomic research
April 2010BioMed receives investment grade corporate credit ratings from Standard & Poor's Rating Services and Moody's Investors Service.
June 2010Strategic real estate partnership with Isis Pharmaceuticals expands with the groundbreaking on a 176,000 square foot build-to-suit research and development facility in Carlsbad, California.

Greg Lubushkin is promoted to Chief Financial Officer.
August 2010BioMed acquires a life science building at 3500 Paramount Parkway in Morrisville, North Carolina within the Research Triangle Park submarket of North Carolina. The building comprises approximately 61,600 square feet which is 100% leased to Bayer CropScience, a wholly owned subsidiary of Bayer AG.
November 2010BioMed acquires two adjacent life science campuses in South San Francisco, California comprising approximately 489,000 square feet of rentable office, laboratory and industrial space. The Science Center at Oyster Point comprises two newly constructed facilities with an aggregate of approximately 205,000 square feet, which are 100% leased on a long-term basis to Elan Corporation. The Gateway Business Park is a research and development park comprised of six buildings with an aggregate of approximately 284,000 square feet, with development rights for an additional 946,000 square feet, which is fully leased to Elan Corporation, FedEx Corporation and Genentech, Inc., a member of the Roche Group.
March – June 2011Harvard University’s Hansjorg Wyss Institute for Biologically Inspired Engineering and Pfizer’s Center for Therapeutic Innovation sign new leases at the Center for Life Science | Boston, bringing the state-of-the-art 18-story building located in the Longwood Medical Area of Boston to 98% leased.
May 2011Logitech, a world leader in personal computer navigation, Internet communications, digital music, home-entertainment control, gaming and wireless devices, signs a new lease at the Pacific Research Center in Newark, California for approximately 263,500 square feet of office space.
June 2011BioMed acquires Ardsley Park, a life science campus in Ardsley, New York, comprising approximately 160,500 square feet of laboratory and office space and 500,000 square feet of future redevelopment and development potential. Concurrently, the company signs a new lease with Acorda Therapeutics, Inc. at Ardsley Park for approximately 138,200 square feet of laboratory and office space.